Article Sidebar

Submitted
13 November 2021
Accepted
6 June 2022
Published
5 June 2022
Download
PDF
Statistic
Read Counter : 870 Download : 244

Main Article Content

Abstract

Highlights:


  1. Uptake of hepatitis B birth dose vaccine within 24 hours of birth is low in Katsina, north-western Nigeria.

  2. The most common reason for delay presentation for hepatitis B birth dose vaccine is maternal illness.



 
Abstract:

No studies focused on the hepatitis B birth dose (HepB-BD) vaccine since Nigeria adopted the strategy to reduce hepatitis B viral infection. Hence, we determined the uptake of HepB-BD, factors associated with timeliness, and those that contributed to delay. This study was a cross-sectional descriptive study carried out at an immunization post in north-western Nigeria. We recruited 400 mother-infant pairs that presented for the first immunization and obtained relevant information, including socio-demographics and reasons for the delays. Of the 400 infants, 44 (11.0%) received HepB-BD within 24 hours (timeliness), 105 (26.3%) and 274 (68.5%) by day 7 and 14, respectively. Multivariate analysis showed that mothers' education (primary adjusted odds (AOR) 17, 95% CI 1.404, 204.611), secondary AOR 5.9, 95% CI 1.148, 29.895), and tertiary AOR 7.7, 95% CI 1.228, 48.545), and third born AOR 8.2, 1.625, 41.018) were associated with HepB-BD timeliness. Maternal-related factors were the commonest (129; 46.6%) for delayed HepB-BD, with maternal illness the most commonly cited reason (37; 28.7%). This study showed a deficient level of uptake of HepB-BD vaccines among infants. Factors that were associated with timeliness included maternal education and higher birth order. The commonest reason for delayed HepB-BD was maternal illness.

Keywords

Hepatitis B birth dose vaccine Hepatitis B viral infection Hepatitis public health newborns

Article Details

License

Copyright (c) 2022 Folia Medica Indonesiana

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

  • Folia Medica Indonesiana is a scientific peer-reviewed article which freely available to be accessed, downloaded, and used for research purposes. Folia Medica Indonesiana (p-ISSN: 2541-1012; e-ISSN: 2528-2018) is licensed under a Creative Commons Attribution 4.0 International License. Manuscripts submitted to Folia Medica Indonesiana are published under the terms of the Creative Commons License. The terms of the license are:

    Attribution ” You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

    NonCommercial ” You may not use the material for commercial purposes.

    ShareAlike ” If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.

    No additional restrictions ” You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

    You  are free to :

    Share ” copy and redistribute the material in any medium or format.

    Adapt ” remix, transform, and build upon the material.

How to Cite
Ibrahim, O. R., Ibraheem, R. M., Aliu, R., & Lawal, I. M. (2022). Factors Associated with Timeliness of Hepatitis B Birth Dose: A Cross-sectional Study in North-Western Nigeria. Folia Medica Indonesiana, 58(2), 129–136. https://doi.org/10.20473/fmi.v58i2.31344
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. Alter MJ (2003). Epidemiology of hepatitis B in Europe and worldwide. J Hepatol 39:64–69.
  2. Ashir G, Rabasa A, Gofama M, et al (2010). Study of hepatic functions and prevalence of Hepatitis B surface Antigenaemia in Nigerian children with human immunodefiency virus infection. Niger J Med 18:260–262.
  3. Chido-Amajuoyi OG, Wonodi C, Mantey D, et al (2018). Prevalence and correlates of never vaccinated Nigerian children, aged 1–5 years. Vaccine 36:6953–6960.
  4. David DS, Ishaya IA, Nathan YS, et al (2020). At"‘birth vaccination timeliness: An analysis of inborns in the Highlands of Jos, North"‘Central Nigeria. Niger Postgrad Med Coll 27:209–214.
  5. Hou J, Liu Z, Gu F (2005). Epidemiology and prevention of hepatitis B virus infection. Int J Med Sci 2:50–57
  6. Ibraheem R, Abdulkadir M, Akintola M, et al (2019). Determinants of Timely Presentation for Birth Dose Vaccination at an Immunization Centre in North-central Nigeria. Ann Glob Heal 85:20.
  7. Jibrin B, Jiya N, Ahmed H (2014). Prevalence of Hepatitis B surface antigen in children with sickle cell anemia. Sahel Med J 17:15.
  8. KasiuleviÄius V, Å apoka V, FilipaviÄiÅ«tÄ— R (2006). Sample size calculation in epidemiological studies. Gerontologija 7:225–231
  9. Lawal MA, Adeniyi OF, Akintan PE, et al (2020). Prevalence of and risk factors for hepatitis B and C viral co-infections in HIV infected children in Lagos, Nigeria. PLoS One 15:e0243656.
  10. Miyahara R, Jasseh M, Gomez P, et al (2016). Barriers to timely administration of birth dose vaccines in The Gambia , West Africa. Vaccine 34:3335–3341.
  11. Moturi E, Tevi-benissan C, Hagan JE, et al (2018). Implementing a birth dose of hepatitis B vaccine in Africa: Findings from assessments in 5 countries. J Immunol Sci S:31–40
  12. Nasidi A, Olayinka AT, Gidado S, et al (2016). Seroprevalence of Hepatitis B Infection in Nigeria: A National Survey. Am J Trop Med Hyg 95:902–907.
  13. National Bureau of Statistics (NBS) and United Nations Children's Fund (UNICEF) (2018) 2017 multiple indicator cluster survey 2016-17, Survey Findings Report. Abuja, Nigeria
  14. Ndako JA, Nwankiti OO, Echeonwu GON, et al (2011). Studies on prevalence and risk factors for hepatitis B surface antigen among secondary school students in North-central, Nigeria. Sierra Leone J Biomed Res 3:163–168
  15. Anh HNS, Vo H-L, Hoang Bao L, et al (2019). Hepatitis B birth dose vaccination among vietnamese children: Implications for the expanded program on immunization. Biomed Res Int 2019:1–8.
  16. Oyedeji GA (1985). Socio-economic and cultural background of hospitalised children in Ilesha. Niger J paed 12:111–117.
  17. Álvarez RAM, Pérez-Vilar S, Pacis-Tirso C, et al (2017). Progress in vaccination towards hepatitis B control and elimination in the Region of the Americas. BMC Public Health 17:325.
  18. Sadoh A, Sadoh W (2014). Does Nigeria need the birth dose of the hepatitis B vaccine? Niger J Paediatr 41:104.
  19. Sadoh AE, Eregie CO (2009). Timeliness and completion rate of immunization among nigerian children attending a clinic-based immunization service. J Heal Popul Nutr 27:391–395.
  20. Sadoh AE, Sadoh WE, Uduebor J, et al (2013). Factors contributing to delay in commencement of Immunisation in Nigerian infants. Tanzan J Health Res 15:1–8.
  21. Stevens CE, Neurath RA, Beasley RP, Szmuness W (1979). HBeAg and anti-hbe detection by radioimmunoassay: Correlation with vertical transmission of hepatitis B virus in Taiwan. J Med Virol 3:237–241.
  22. Trépo C, Chan HLY, Lok A (2014). Hepatitis B virus infection. Lancet 384:2053–2063.
  23. Wiesen E, Diorditsa S, Li X (2016). Progress towards hepatitis B prevention through vaccination in the Western Pacific, 1990–2014. Vaccine 34:2855–2862.
  24. World Health Organisation (2017). Hepatitis B vaccines: WHO position paper – July 2017 Introduction. Wkly Epidemiol Rec 92:369–392
  25. World Health Organization (2020a) Public Health significance, targets, strategies. Available from https://whohbsagdashboard.surge.sh/#public-health-strategies. Accessed May 24, 2021
  26. World Health Organization (2007). Global hepatitis report 2017. Geneva
  27. World Health Organization (2020b). Hepatitis B-Key fact sheets. Available from https://www.who.int/news-room/fact-sheets/detail/hepatitis-b. Accessed May 24, 2021
  28. World Health Organization (2016a). Global health sector strategy on viral hepatitis 2016–2021. Geneva
  29. World Health Organization (2016b). Global compliance with Hepatitis B vaccine birth dose and factors related to timely schedule. A review. Geneva